SciTech Development LLC

United States - Grosse Pointe Farms, MI

• 08/06/2023
• Unknown
• $2,730,000

SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer treatments. SciTech’s innovations and pipeline will impact our mission to develop cost-effective therapeutics that deliver transformative clinical outcomes.

SCITECH DEVELOPMENT LLC

Introducing Our Revolutionary New Drug Delivery Platform (SDP) and Lead Cancer Drug Candidate ST-001 nanoFenretinide.

● Our proprietary Drug Delivery Platform, called SDP, has enormous potential to develop and deliver new and better drugs for incurable cancers.
● ST-001-nanoFenretinide is our first, patented drug, that combines SDP and the drug fenretinide as a broadly applicable anticancer drug.
● Fenretinide presents a low-risk scenario as it has been shown to be safe and effective in both children and adults in previous clinical trials.
● ST-001 is clinical trial ready!

OUR GOAL

Our immediate goal is to commercialize ST-001 and develop strategic partnerships with companies in the pharmaceutical industry who are looking to expand their existing drug portfolio in oncology, target new diseases, or develop combination drug therapies.

OUR HIGHLIGHTS AND ACHIEVEMENTS

• IND for T-Cell Lymphomas approved by the FDA
• FDA approved Phase 1a/b (equivalent to traditional Phase 1 & 2) clinical trial plan
• IRB Approved by Rush University Medical Center to start clinical trials
• Orphan Drug Designation granted for several T-cell lymphomas
• SDP can be used to solve bioavailability and delivery issues in many other drugs
• SDP has potential application for treating additional cancers and other diseases
• ST-001 has potential use as a companion therapeutic with other already approved drugs
• Affordable treatment cost to patients and for payors

Related People

Earle Holsapple IIIFounder

United States - Detroit, Michigan,

Now that SciTech is clinic ready, we are focused on commencing the clinical trials to confirm the potential of two platform technologies: 1) the de-risked therapeutic opportunities of the active drug fenretinide with prior human efficacy data and a rapid runway to market and 2) the nano formulation/manufacturing platform that provides a gateway to many therapeutic avenues. With an unprecedented opportunity to monetize our patented delivery system for use in other drugs and to reconfirm the efficacy of our active drug, our team has commenced an all hands effort to raise the required capital to fund the trial.

LinkedIn https://www.linkedin.com/in/earle-holsapple-iii-7837947/